Piramal Invests $30.6 Million in Coldstream Acquisition
Piramal Enterprises (PEL) announced on Jan. 16, 2015 that it had invested $30.6 million USD toward the acquisition of Coldstream Laboratories, a contract development and manufacturing organization focused on the development and manufacture of sterile injectables, in an all cash transaction. Of this investment, $5.6 million would be used to purchase Coldstream’s facility, adding to PEL’s multiple “Pharma Solutions” facilities in India, as well as locations in Canada and the UK, according to the website. The rest of the investment would go toward 100% of the company’s shares.
Coldstream is majority owned by the University of Kentucky Research Foundation, and operates from a facility in Lexington, Kentucky. According to the company website, it offers a variety of drug product manufacturing services including liquid and lyophilized parenterals, process development and optimization, terminal sterilization, aseptic and non-aseptic pilot scale manufacturing, preclinical to Phase III manufacturing, and niche commercial products. (http://www.coldstreamlabs.com/contract-manufacturing/)
Source:
Piramal
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
